Association of beta 2 microglobulin level and glomerular filtration rate in patients with acute leukemia after hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation is a life-saving therapy in patients suffering from acute leukemia. However, kidney complications developed after performing hematopoietic stem cell transplantation can affect the course and prognosis of the disease in patients with acute leukemia. This study is aimed at assessing the functional status of the kidneys in patients with acute leukemia who have undergone hematopoietic stem cell transplantation. The study has observed a group of patients with acute lymphoblastic leukemia and acute myeloid leukemia who have undergone hematopoietic stem cell transplantation. It has been discovered that beta 2 microglobulin is a sensitive method of analyzing renal function, with the beta 2 microglobulin threshold urine level not exceeding 0.3 mg/L. The complex diagnostics of kidney function in hematopoietic stem cell transplantation recipients has given the opportunity to identify the relationship between increased beta 2 microglobulin levels and decreased glomerular filtration rate. It has been determined that beta 2 microglobulin is a biomarker of renal disorders. The obtained data have showed that beta 2 microglobulin can be used as a diagnostic marker of reduced kidney function.